IMO-T 2.13 CGI-T -0.07 AC-T -0.05 LNR-T 1.37 LLY-N 2.04 META-Q 0.82 NVDA-Q -0.21
Daily Stock Opinions and Ratings
Stockchase Opinions

David Baskin Dimethaid DMX-T DON'T BUY Jan 25, 2005

Very much news driven. Speculative. Need a very strong stomach.
David BaskinDavid Baskin
No
Unlock Rating
$0.400

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

BUY

Dimethaid(DMX-T)

Oct 13, 2000
Good techs. Have to convince the Feds its a good way to deliver pain relief
Glenn Paradis, BA, CFAGlenn Paradis, BA, CFA
Unknown
Unlock Rating
$5.000

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

Dimethaid(DMX-T)

Nov 29, 2000
Not a big enough following but should be OK
Pier DonniniPier Donnini
Unknown
Unlock Rating
$5.600

Stock price when the opinion was issued

biotechnology pharmaceutical
WATCH

Dimethaid(DMX-T)

Jan 02, 2001
Attractive, but wait for partnership deal with Johnson & Johnson
Steven MisenerSteven Misener
Unknown
Unlock Rating
$8.100

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

Dimethaid(DMX-T)

Mar 19, 2001
Approaching commercialization.
Ed HoEd Ho
Unknown
Unlock Rating
$7.250

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

Dimethaid(DMX-T)

Mar 27, 2003
A this point, its a reasonable bet.
Robert FloydRobert Floyd
Unknown
Unlock Rating
$2.090

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Dimethaid(DMX-T)

Jul 03, 2003
Has been losing value for some time. Need to have a lot of faith. They are still waiting for a green light from the FDA. The big risk is their inability to move sales.
Lou SchizasLou Schizas
Unknown
Unlock Rating
$1.740

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Dimethaid(DMX-T)

Nov 27, 2003
Looked like it was going to break out of a 200-day moving average but fell back. Did a special warrant financing in October for sales/marketing of Pennsaid. FDA approval has been pending for a long time. Caution.
Lou SchizasLou Schizas
Unknown
Unlock Rating
$1.330

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Dimethaid(DMX-T)

Sep 15, 2005
New management. Doesn't follow this company actively because it doesn't have much in the way of earnings. In the bottom 10% of his database.
Robert McWhirterRobert McWhirter
No
Unlock Rating
$0.185

Stock price when the opinion was issued

biotechnology pharmaceutical

Your Watchlist

Add stocks to watchlist to monitor them daily and get important alerts.

Latest Buy Signals

HRTG-N -0.007$18.863
EIF-T 0.37$48.84
MRK-N 0.35$78.35
MDI-T -0.11$8.3
DBM-T 0.03$6.86
Advertising

Today's Top Picks

IMO-T 2.13$88.37
CGI-T -0.07$33
AC-T -0.05$13.97
LNR-T 1.37$48.15
LLY-N 2.04$842

Popular Articles

Questrade Review: Pros & Cons of Trading with Questrade Canada (2021) Steady Eddys: 3 Stable Stocks Between Safety and Risk: 3 Safe and Gambling Stocks 3 Oversold Stocks to Take Advantage of 5 ETFs for Index Investing

Latest Sell Signals

RH-N 0.12$161.25
LVMUY-… 0$109.54
NXPI-Q 0.18$170.92
DAL-N 0.07$40.92
AMD-Q -0.03$87.47

Most Recent Experts

Bruce Murray

The Murray Wealth Group

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Chris Blumas

at Raymond James Investment Counsel Ltd.

Stockchase Insights

5i Research

Advertising
Advertising
© Stockchase Inc.